Concomitant Cardiac Surgical Procedures in Patients Undergoing HeartMate 3 Left Ventricular Assist Device Implantation.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: The Association Country of Publication: Israel NLM ID: 100930740 Publication Model: Print Cited Medium: Internet ISSN: 1565-1088 (Print) NLM ISO Abbreviation: Isr Med Assoc J Subsets: MEDLINE
    • Publication Information:
      Original Publication: Ramat Gan, Israel : The Association, c1999-
    • Subject Terms:
      Heart-Assist Devices*/statistics & numerical data ; Heart Failure*/surgery ; Heart Failure*/mortality ; Heart Failure*/therapy ; Cardiac Surgical Procedures*/methods; Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; Treatment Outcome ; Prosthesis Implantation/methods
    • Abstract:
      Background: Long-term support with a HeartMate 3 (HM3) left ventricular assist device (LVAD) has improved outcomes of patients with end-stage heart failure. However, there is a paucity of data on the outcomes of patients who underwent concomitant cardiac surgical procedure (CCSP) during HM3-LVAD implantation.
      Objectives: To assess our single-center experience with patients who underwent CCSP during the implantation of an HM3-LVAD.
      Methods: From December 2016 until April 2022, 131 adult patients underwent HM3-LVAD implantation. A total of 23 patients underwent CCSP during the HM3-LVAD implantation+CCSP, and 108 underwent only HM3-LVAD implantation (HM3-only).
      Results: The median age was 59 ± 11 years (range 54-67), 82% (n=108) were male, and 76% (n=100) were implanted as a bridge-to-transplant. The concomitant procedures performed during the implantation included 8 aortic valve repairs/replacements, 14 tricuspid valve repairs, 4 patent foramen ovales or atrial septal defect closures, and 3 other cardiac procedures. The mean cardiopulmonary bypass time was 113 ± 58 minutes for the HM3-only group and 155 ± 47 minutes for the HM3+CCSP group (P = 0.007). The mortality rates at 30 days, 6 months, and 12 months post-implantation were 2 (9%), 5 (22%), and 6 (26%) respectively for the HM3+CCSP group, and 7 (6%), 18 (17%), and 30 (28%) for the HM3-only group (P = 0.658, 0.554, and 1.000).
      Conclusions: Our experience demonstrated no significant difference in the 30-day, 6-month, and 12-month mortality rates for patients who underwent a CCSP during HM3-LVAD implantation compared to patients who did not undergo CCSP during HM3-LVAD implantation.
    • Publication Date:
      Date Created: 20240513 Date Completed: 20240513 Latest Revision: 20240513
    • Publication Date:
      20240513
    • Accession Number:
      38736341